Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | ctDNA-guided therapy: transforming treatment decisions across tumor types

Joaquim Bellmunt • 30 May 2026
ASCO 2026
Bladder Cancer Genitourinary Cancer Antibodies Atezolizumab Checkpoint Inhibitors
IMvigor011

Joaquim Bellmunt, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, comments on the significance of the IMvigor011 trial (NCT04660344) in personalizing adjuvant therapy using circulating tumor DNA (ctDNA) and its potential to change the treatment paradigm. Similar approaches are being explored in other trials, such as bladder preservation, where monitoring minimal residual disease through blood and urinary tumor DNA (utDNA) is becoming increasingly important. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Joaquim Bellmunt

Patient-reported outcomes from IMvigor011: adjuvant atezolizumab in MIBC
2:13
Patient-reported outcomes from IMvigor011: adjuvant atezolizumab in MIBC
Joaquim Bellmunt • 30 May 2026
ctDNA in bladder cancer: interpreting results and clinical limitations
1:56
ctDNA in bladder cancer: interpreting results and clinical limitations
Joaquim Bellmunt • 28 Feb 2026
Will ctDNA becoming a routine postoperative risk stratification tool in MIBC?
4:01
Will ctDNA becoming a routine postoperative risk stratification tool in MIBC?
Joaquim Bellmunt • 28 Feb 2026
IMvigor011: ctDNA dynamics in MIBC treated with adjuvant atezolizumab
5:02
IMvigor011: ctDNA dynamics in MIBC treated with adjuvant atezolizumab
Joaquim Bellmunt • 28 Feb 2026

Related Videos

New approaches to curing bladder and kidney cancers: where do we stand?
3:07
New approaches to curing bladder and kidney cancers: where do we stand?
Srikala Sridhar • 30 May 2026
Predictive biomarkers in bladder & kidney cancer: insights into recent progress
0:33
Predictive biomarkers in bladder & kidney cancer: insights into recent progress
Srikala Sridhar • 30 May 2026
Evaluating the current data for CDK4/6 inhibition in resistant prostate cancer
0:47
Evaluating the current data for CDK4/6 inhibition in resistant prostate cancer
Kevin Zarrabi • 29 May 2026
Patient-reported outcomes from IMvigor011: adjuvant atezolizumab in MIBC
2:13
Patient-reported outcomes from IMvigor011: adjuvant atezolizumab in MIBC
Joaquim Bellmunt • 30 May 2026
The content of VJOncology is intended for healthcare professionals